161 related articles for article (PubMed ID: 36611001)
41. Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.
Villagra D; Goethe J; Schwartz HI; Szarek B; Kocherla M; Gorowski K; Windemuth A; Ruaño G
Biomark Med; 2011 Aug; 5(4):427-38. PubMed ID: 21861665
[TBL] [Abstract][Full Text] [Related]
42. Diversity of pharmacogenomic variants affecting warfarin metabolism in Sri Lankans.
Ranasinghe P; Sirisena N; Senadeera V; Anandagoda G; Dissanayake VH
Pharmacogenomics; 2022 Nov; 23(17):917-923. PubMed ID: 36285665
[No Abstract] [Full Text] [Related]
43. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.
Semiz S; Dujic T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Marc J; Causevic A
Bosn J Basic Med Sci; 2010 Nov; 10(4):287-91. PubMed ID: 21108610
[TBL] [Abstract][Full Text] [Related]
44. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
45. Pharmacogenetics: from bench to byte--an update of guidelines.
Swen JJ; Nijenhuis M; de Boer A; Grandia L; Maitland-van der Zee AH; Mulder H; Rongen GA; van Schaik RH; Schalekamp T; Touw DJ; van der Weide J; Wilffert B; Deneer VH; Guchelaar HJ
Clin Pharmacol Ther; 2011 May; 89(5):662-73. PubMed ID: 21412232
[TBL] [Abstract][Full Text] [Related]
46. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
Nagler M; Angelillo-Scherrer A; Méan M; Limacher A; Abbal C; Righini M; Beer JH; Osterwalder J; Frauchiger B; Aschwanden M; Matter CM; Kucher N; Cornuz J; Banyai M; Husmann M; Staub D; Mazzolai L; Hugli O; Rodondi N; Aujesky D
J Thromb Haemost; 2017 Nov; 15(11):2165-2175. PubMed ID: 28834238
[TBL] [Abstract][Full Text] [Related]
47. Frequency of selected single nucleotide polymorphisms influencing the warfarin pharmacogenetics in Slovak population.
Krajčíová L; Petrovič R; Déžiová L; Chandoga J; Turčáni P
Eur J Haematol; 2014 Oct; 93(4):320-8. PubMed ID: 24750390
[TBL] [Abstract][Full Text] [Related]
48. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
49. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM; Zehnbauer B; Wilson JA; Baak R; Babic N; Bettinotti M; Buller A; Butz K; Campbell M; Civalier C; El-Badry A; Farkas DH; Lyon E; Mandal S; McKinney J; Muralidharan K; Noll L; Sander T; Shabbeer J; Smith C; Telatar M; Toji L; Vairavan A; Vance C; Weck KE; Wu AH; Yeo KT; Zeller M; Kalman L
J Mol Diagn; 2010 Nov; 12(6):835-46. PubMed ID: 20889555
[TBL] [Abstract][Full Text] [Related]
50. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens.
Kehinde O; Ramsey LB; Gaedigk A; Oni-Orisan A
Clin Pharmacol Ther; 2023 Jul; 114(1):69-76. PubMed ID: 36924260
[TBL] [Abstract][Full Text] [Related]
51. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
52. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
53. Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.
Mazzaccara C; Conti V; Liguori R; Simeon V; Toriello M; Severini A; Perricone C; Meccariello A; Meccariello P; Vitale DF; Filippelli A; Sacchetti L
PLoS One; 2013; 8(8):e71505. PubMed ID: 23990957
[TBL] [Abstract][Full Text] [Related]
54. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T; Miyata T
Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
[TBL] [Abstract][Full Text] [Related]
55. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
[TBL] [Abstract][Full Text] [Related]
57. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.
Mizzi C; Dalabira E; Kumuthini J; Dzimiri N; Balogh I; Başak N; Böhm R; Borg J; Borgiani P; Bozina N; Bruckmueller H; Burzynska B; Carracedo A; Cascorbi I; Deltas C; Dolzan V; Fenech A; Grech G; Kasiulevicius V; Kádaši Ľ; Kučinskas V; Khusnutdinova E; Loukas YL; Macek M; Makukh H; Mathijssen R; Mitropoulos K; Mitropoulou C; Novelli G; Papantoni I; Pavlovic S; Saglio G; Setric J; Stojiljkovic M; Stubbs AP; Squassina A; Torres M; Turnovec M; van Schaik RH; Voskarides K; Wakil SM; Werk A; Del Zompo M; Zukic B; Katsila T; Lee MT; Motsinger-Rief A; Mc Leod HL; van der Spek PJ; Patrinos GP
PLoS One; 2016; 11(9):e0162866. PubMed ID: 27636550
[TBL] [Abstract][Full Text] [Related]
58. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
Seeringer A; Kirchheiner J
Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
[TBL] [Abstract][Full Text] [Related]
59. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
[TBL] [Abstract][Full Text] [Related]
60. Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.
Deneer VH; van Schaik RH
Methods Mol Biol; 2013; 1015():345-54. PubMed ID: 23824868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
